stock-detail (BIND)

Oncology Corporate Profile

Company Description

This company does not have any commercial products

This company does not have any pipeline products

Recent News Headlines

BIND Therapeutics Determines Pfizer's $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND's Assets

7/26/2016 09:04 pm

[at noodls] - July 26, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that ...

BIND Therapeutics Determines Pfizer’s $40 Million Bid Is Highest and Best in 363 Auction for Substantially All of BIND’s Assets

7/26/2016 09:02 pm

[Business Wire] - BIND Therapeutics, Inc. , a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that Pfizer Inc. prevailed at a Section 363 auction to purchase substantially all of BIND’s assets.

BIND Therapeutics Announces Two Bidders Join Pfizer's Stalking Horse Bid in Auction for BIND's Assets

7/25/2016 11:05 am

[at noodls] - July 25, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ:BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that ...

BIND Therapeutics Announces Two Bidders Join Pfizer’s Stalking Horse Bid in Auction for BIND’s Assets

7/25/2016 11:00 am

[Business Wire] - BIND Therapeutics, Inc. , a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced that it has received two bids that are qualified to participate in the Court authorized auction beginning at 10 a.m.

BIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer Inc.

7/1/2016 09:05 pm

[at noodls] - July 1, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS, today announced it has ...

BIND Therapeutics Files Motion for Sale of Assets After Accepting Stalking Horse Bid from Pfizer Inc.

7/1/2016 09:03 pm

[Business Wire] - BIND Therapeutics, Inc. , a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced it has filed a motion for court approval of a stalking horse asset purchase agreement bid from Pfizer Inc.

BIND Therapeutics Announces Resignation of Directors Affiliated with Polaris Partners

6/17/2016 02:01 pm

[at noodls] - June 17, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced the ...

BIND Therapeutics Announces Resignation of Directors Affiliated with Polaris Partners

6/17/2016 01:00 pm

[Business Wire] - BIND Therapeutics, Inc. , a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced the resignations of Amir Nashat, managing partner at Polaris Partners, and Amy Schulman, venture partner at Polaris Partners and chief executive officer at Arsia Therapeutics and Lyndra Therapeutics, from BIND’s Board of Directors.

BIND Therapeutics Provides Update on Chapter 11 Proceedings and Announces Agreement with Hercules Technology III, L.P.

5/19/2016 12:03 pm

[at noodls] - May 19, 2016 CAMBRIDGE, Mass.--(BUSINESS WIRE)-- BIND Therapeutics, Inc. (NASDAQ: BIND), a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced an agreement ...

BIND Therapeutics Provides Update on Chapter 11 Proceedings and Announces Agreement with Hercules Technology III, L.P.

5/19/2016 12:00 pm

[Business Wire] - BIND Therapeutics, Inc. , a biotechnology company developing targeted and programmable therapeutics called ACCURINS®, today announced an agreement has been reached with its secured lender Hercules Technology III, L.P., an affiliate of Hercules Capital , for the use of cash collateral through July 8, 2016 subject to certain agreed upon terms and conditions.